Seattle-based Swedish Cancer Institute joined forces with GNS Healthcare, a precision medicine company, to launch a machine learning collaboration aimed at improving the delivery of precision medicine in breast cancer care.
GNS will use its causal machine learning and simulation platform REFS to build computer models and a software interface tool linking SCI's clinical data to treatment options and outcomes. GNS will use data from SCI's Breast Cancer Research Registry and Personalized Medicine Research Program to build the computer models and tools. The collaboration aims to improve clinical decision making, as providers can use the models to simulate potential treatments and outcomes.
"Few oncologists today have the complete training or time necessary to decipher complex results of a tumor's biologic fingerprint. GNS' REFS-generated models will streamline this process and enhance our PMRP's work to support providers and their patients with treatment recommendations," said Thomas Brown, MD, executive director of SCI.
The collaboration showcases a framework for scaling precision medicine initiatives within the breast cancer care arena.